Erratum to: Masked polycythemia Vera (mPV): Results of an international study (American Journal of Hematology, (2014), 89, 1, (52-54), 10.1002/ajh.23585);Masked polycythemia Vera (mPV): Results of an international study

American Journal of Hematology

Volumn 89, Issue 1, 2014, Pages 52-54

  Barbui, Tiziano ^a   Thiele, Jürgen ^b   Gisslinger, Heinz ^c   Finazzi, Guido ^a   Carobbio, Alessandra ^a   Rumi, Elisa ^d   Luigia Randi, Maria ^e   Betozzi, Irene ^e   Vannucchi, Alessandro M ^f   Pieri, Lisa ^f   Carrai, Valentina ^f   Gisslinger, Bettina ^c   Müllauer, Leonhard ^c   Ruggeri, Marco ^g   Rambaldi, Alessandro ^a   Tefferi, Ayalew ^h  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g SAN BORTOLO HOSPITAL   (Italy)

^h MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ACUTE LEUKEMIA; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BONE MARROW; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ERYTHROCYTE INDICES; EXONS; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; RISK FACTORS; THROMBOSIS;

EID: 84892882972     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.25069     Document Type: Erratum

References (23)

1. Spivak JL. Polycythemia vera: Myths, mechanisms, and management. Blood. 2002;100:4272-4290.
2. Thiele J, Kvasnicka HM, Orazi A, et al. Polycythemia vera. In: Swerdlow S, Campo E, Harris N, et al., editors. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. Lyon, France: IARC Press; 2008. pp 40-43.
3. Silver RT, Chow W, Vandris K, et al. Prospective evaluation of the World Health Organization criteria for the diagnosis of polycythemia vera. Blood (ASH Annual Meeting Abstracts) 2011;118:3837.
4. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol 2005;129:701-705.
5. Alvarez-Larran A, Anchocea A, Angona A, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 2012;97:1704-1707.
6. McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythemia/erythrocytosis. Br J Haematol 2005;130:174-195.
7. Tefferi A. The rise and the fall of red cell mass measurement in polycythemia vera. Curr Hematol Rep 2005;4:213-217.
8. Sirhan S, Fairbanks VF, Tefferi A. Red cell mass and plasma volumen measurements in polycythemia: Evaluation of performance and practical utility. Cancer 2005;104:213-215.
9. Ellis JT, Silver RT, Coleman M, Geller SA. The bone marrow in polycythemia vera. Semin Hematol 1975;12:433-444.
10. Ellis JT, Peterson P, Geller SA, Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144-115.
11. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol 2005;20:317-328.
12. Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol 2005;113:213-219.
13. Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol 2008;30:336-342.
14. Kvasnicka HM, Thiele J. Prodromal myeloproliferative neoplasms: The 2008 WHO classification. Am J Hematol 2010;85:62-66.
15. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013. DOI 10.1038/leu.2013.74.
16. Madelung AB, Bondo H, Stamp I, et al. World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-the Danish experience. Am J Hematol 2013. DOI 10.1002/ajh.23554.
17. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119:2239-2241.
18. Tefferi A. Diagnosing polycythemia vera: A paradigma shift. Mayo Clin Proc 1999;74:159-162.
19. Mossuz P, Girodon F, Donnand M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004;89;1194-1198.
20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
21. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013. DOI 10.1038/leu.2013.163.
22. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 2011;;29:761-770.
23. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.